Purchase this article with an account.
N. Sun, C. J. Patel, R. M. Lieberman, R. M. Fischer; Effect of Intravitreal Bevacizumab (Avastin®) on the Area of the Foveal Avascular Zone in the Injected and Contralateral Eye in a Diverse Clinic Population. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3578.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To examine the effect of a single intravitreal injection of bevacizumab (Avastin®) on the area of the foveal avascular zone (FAZ) in both the injected and the contralateral eye in a diverse clinic population.
A retrospective chart review of 23 patients each having received a single intravitreal injection of bevacizumab was conducted. The area of the FAZ was measured on fluorescein angiograms during the arterial phase in both the injected and the contralateral eyes. Data was collected prior to treatment and at 1 and 3 months after treatment. Additional data included demographics, diagnoses at time of injection and HA1c levels.
Of the 23 patients (46 eyes) included, there were 12 Hispanics, 8 Asians, 2 Blacks, and 1 Caucasian. Diagnoses at the time of injection included 20 diabetic retinopathy, 2 CRVO, and 1 BRVO. The mean FAZ area in the injected eyes prior to treatment was 0.53mm², with a range of 0.22 to 1.08 mm². The mean FAZ area of the contralateral eyes was 0.54mm², with a range of 0.22 to 0.82mm². At 1 month post injection, the mean FAZ of the injected eyes showed a 6.07% decrease from baseline to a mean of 0.50mm² (p=0.0982). The contralateral eyes showed a 1.20% decrease to a mean of 0.53mm² (p=0.5939). At 3 months post injection, there was a significant decrease from baseline in the mean FAZ area of the injected eyes by 8.77% to a mean of 0.48 mm² (p=0.0478). The contralateral eye group showed a decrease of 2.51% to a mean of 0.52mm² (p=0.2075). Correlation was analyzed with respect to HA1c levels in both groups.
We found a decrease in the overall area of the FAZ at both 1 and 3 months post injection, with a statistically significant decrease at 3 months in eyes injected with bevacizumab. In the contralateral eyes, the FAZ area also decreased at both 1 and 3 months, but neither group reached statistical significance. These findings may further contribute to the safety profile of intravitreal bevacizumab. Further study is warranted on the effects of multiple bevacizumab injections with greater length of follow-up.
This PDF is available to Subscribers Only